Prostate-specific Membrane Antigen Biology in Lethal Prostate Cancer and its Therapeutic Implications

Therapeutic Implications ◽

Oncogenic Pathways ◽

In this issue of JEM, Kaittanis et al. (https://doi.org/10.1084/jem.20171052) report a new signaling role for prostate-specific membrane antigen (PSMA), providing a mechanistic link between two major oncogenic pathways, as well as promising therapeutic implications for the diagnosis and treatment of prostate cancer.

Prostate-Specific Membrane Antigen Protein Expression in Tumor Tissue and Risk of Lethal Prostate Cancer

Cancer Epidemiology Biomarkers & Prevention ◽

10.1158/1055-9965.epi-13-0668 ◽

2013 ◽

Vol 22 (12) ◽

pp. 2354-2363 ◽

Cited By ~ 42

Author(s):

Julie L. Kasperzyk ◽

Stephen P. Finn ◽

Richard Flavin ◽

Michelangelo Fiorentino ◽

Rosina Lis ◽

...

Keyword(s):

Prostate Cancer ◽

Protein Expression ◽

Tumor Tissue ◽

Antigen Protein ◽

Specific Membrane ◽

Lethal Prostate Cancer

479: Prostate-Specific Membrane Antigen (PSMA) Expression as a Predictor of Prostate Cancer Progression

The Journal of Urology ◽

10.1016/s0022-5347(18)32735-6 ◽

2006 ◽

Vol 175 (4S) ◽

pp. 155-156

Author(s):

Matthias D. Hofer ◽

Sven Perner ◽

Haojie Li ◽

Rainer Kuefer ◽

Richard E. Hautmann ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Progression ◽

Prostate Cancer Progression ◽

Specific Membrane ◽

Psma Expression

Prostate specific membrane antigen targeted radioligand therapy of metastatic castration-resistant prostate cancer using Lu-177 PSMA-617: safety, efficacy and dosimetry in comparison with Lu-177 PSMA I&T

Endocrine Abstracts ◽

10.1530/endoabs.47.oc32 ◽

2016 ◽

Author(s):

Harshad R. Kulkarni ◽

Aviral Singh ◽

Christiane Schuchardt ◽

Karin Niepsch ◽

Richard P. Baum

Keyword(s):

Prostate Cancer ◽

Castration Resistant Prostate Cancer ◽

Radioligand Therapy ◽

Castration Resistant ◽

Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer

European Urology ◽

10.1016/j.eururo.2021.03.017 ◽

2021 ◽

Author(s):

Carissa E. Chu ◽

Mohammed Alshalalfa ◽

Martin Sjöström ◽

Shuang G. Zhao ◽

Yang Liu ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Features ◽

Molecular Subtypes ◽

Primary Prostate Cancer ◽

Clinical Translation of Positive Metastases Identified on Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging in the Management of De Novo Synchronous Oligometastatic Prostate Cancer

European Urology Focus ◽

10.1016/j.euf.2020.12.002 ◽

2020 ◽

Author(s):

Martin J. Connor ◽

Suriaya Dubash ◽

Edward J. Bass ◽

Henry Tam ◽

Tara Barwick ◽

...

Keyword(s):

Prostate Cancer ◽

Computed Tomography ◽

De Novo ◽

Emission Tomography ◽

Computed Tomography Imaging ◽

Tomography Imaging ◽

Positron Emission ◽

Oligometastatic Prostate Cancer ◽

225Actinium-labeled prostate-specific membrane antigen targeting peptide induces complete response in a metastatic prostate cancer patient

Acta Radiologica Open ◽

10.1177/20584601211022509 ◽

2021 ◽

Vol 10 (5) ◽

pp. 205846012110225

Author(s):

Omer Aras ◽

Stefan Harmsen ◽

Richard Ting ◽

Haluk B Sayman

Keyword(s):

Prostate Cancer ◽

Standard Of Care ◽

Complete Response ◽

Limited Data ◽

Castrate Resistant Prostate Cancer ◽

Targeting Peptide ◽

Castrate Resistant ◽

Targeted radionuclide therapy has emerged as a promising and potentially curative strategy for high-grade prostate cancer. However, limited data are available on efficacy, quality of life, and pretherapeutic biomarkers. Here, we highlight the case of a patient with prostate-specific membrane antigen (PSMA)-positive metastatic castrate-resistant prostate cancer who displayed complete response to 225Ac-PSMA-617 after having been resistant to standard-of-care therapy, then initially partially responsive but later resistant to subsequent immunotherapy, and resistant to successive 177Lu-PSMA-617. In addition, the patient’s baseline germline mutation likely predisposed him to more aggressive disease.